Therapeutic Management of Nonmetastatic Prostate Cancer
January 2014
January 2016
November 2017
Darolutamide Plus ADT Shows Promise in Treating Metastatic Prostate Cancer
July 17th 2024Findings from the phase 3 ARANOTE trial demonstrated an improvement in radiographic progression-free survival with darolutamide vs placebo plus androgen deprivation therapy in metastatic hormone-sensitive prostate cancer.
Read More